

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

CLARIFICATION ANNOUNCEMENT

This announcement is made by CanSino Biologics Inc. (the “**Company**”) on a voluntary basis.

The Company has noticed certain media reports related to the production and transportation of COVID-19 vaccines by a vaccine company located in Tianjin.

The Company hereby makes following statements and clarifications to prevent the shareholders of the Company (the “**Shareholders**”) and potential investors of the Company from being misled:

1. After the Company’s Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation (the “**Ad5-nCoV for Inhalation**”) has been included for emergency use as a booster vaccine in the PRC, the Company attaches great importance to its production and transportation capacities. The production capacity for the Ad5-nCoV for Inhalation of the Company is 1.5 million doses per day. The Company reaches a transportation capacity for the Ad5-nCoV for Inhalation of 1 million doses per day, not “ships at least 1 million doses nationwide every day”.
2. The Company will continuously support the work related to pandemic prevention and control and make its contribution to the fight against the pandemic.

Save as disclosed in this announcement, after having made all reasonable enquiries with the Company, the Board of Directors confirms that it is not aware of any other information which must be announced to avoid a false market in the Company’s securities or any inside information that needs to be disclosed under the Inside Information Provisions (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited) under Part XIVA of the Securities and Futures Ordinance.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, November 25, 2022

As of the date of this announcement, the Board comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU, Dr. Dongxu QIU and Ms. Jing WANG as executive Directors, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive Directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive Directors.